Quantbot Technologies LP Trims Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Quantbot Technologies LP cut its position in Omnicell, Inc. (NASDAQ:OMCL) by 14.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,581 shares of the company’s stock after selling 3,100 shares during the quarter. Quantbot Technologies LP’s holdings in Omnicell were worth $810,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the company. Pacer Advisors Inc. increased its holdings in shares of Omnicell by 32.6% in the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock worth $56,047,000 after purchasing an additional 508,789 shares during the period. Dimensional Fund Advisors LP increased its stake in Omnicell by 0.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock worth $31,955,000 after acquiring an additional 3,570 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of Omnicell by 11,982.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock valued at $50,071,000 after acquiring an additional 1,138,921 shares in the last quarter. Federated Hermes Inc. boosted its position in shares of Omnicell by 1,113.6% during the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after acquiring an additional 909,480 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. bought a new stake in shares of Omnicell during the 3rd quarter valued at about $32,721,000. 97.70% of the stock is owned by institutional investors.

Omnicell Stock Down 3.9 %

NASDAQ OMCL opened at $46.59 on Monday. The company has a 50-day simple moving average of $44.55 and a two-hundred day simple moving average of $38.05. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.74. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of -119.46, a PEG ratio of 35.40 and a beta of 0.81.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on OMCL shares. Craig Hallum raised their target price on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company raised their price objective on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research report on Monday, October 14th. JPMorgan Chase & Co. lifted their price objective on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Benchmark reissued a “buy” rating and issued a $48.00 target price on shares of Omnicell in a research note on Wednesday, October 9th. Finally, StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research note on Wednesday, November 27th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, Omnicell currently has an average rating of “Hold” and an average price target of $52.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.